Systemic lupus erythematosus (SLE): cross-border specialty drug access for international patients

Quick orientation

SLE affects an estimated 20 to 150 per 100,000 people globally, with substantial regional and ethnic variation. Female predominance is approximately 9 to 1.

Typical age of onset. Most commonly diagnosed between ages 15 and 45.

Severity tiers. Severity ranges from mild cutaneous and joint disease to severe organ-threatening involvement (renal, neurologic, hematologic).

Why specialty drugs for Systemic lupus erythematosus (SLE) are hard to access internationally

Several recent FDA approvals for SLE including type I interferon receptor antagonists and B-cell targeting agents are not yet registered in many MENA and South Asian markets despite substantial disease burden there.

Treatments approved by the FDA

• Saphnelo (anifrolumab) — FDA approval: 2021. Mechanism: Type I interferon receptor antagonist. Route: Intravenous infusion every 4 weeks. US WAC ballpark: Approximately USD 50,000 per year.
• Benlysta (belimumab) — FDA approval: 2011 (lupus nephritis 2020). Mechanism: BLyS-specific inhibitor. Route: Subcutaneous weekly or intravenous monthly. US WAC ballpark: Approximately USD 50,000 per year.
• Rinvoq (upadacitinib) — FDA approval: 2019. Mechanism: Oral selective JAK1 inhibitor (off-label use in lupus). Route: Oral once daily. US WAC ballpark: Approximately USD 70,000 per year. Country pricing: UAE · Saudi Arabia · India · Egypt.

Cross-border pathways used for Systemic lupus erythematosus (SLE)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• Cross-border Prescription

What your physician needs to know

• Confirm SLE diagnosis using ACR/EULAR criteria.
• Document organ involvement and disease activity (SLEDAI or similar).
• Screen for infection risk before initiating biologic therapy.
• Update vaccinations before immunomodulator initiation.
• Rheumatologist co-management is essential.

Common questions

How do I choose between biologics?

Choice depends on disease manifestations, prior therapy, and patient factors. Your rheumatologist decides.

Are these drugs available locally?

Belimumab is more widely registered globally; anifrolumab is newer and narrower. We confirm by destination.

Can I combine biologics?

Typically not. Sequential use is more common.

How long does shipment take?

Five to ten business days from prescription receipt.

What documents are required?

Rheumatologist's prescription, recent labs including ANA and dsDNA, organ-system review, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Systemic lupus erythematosus (SLE), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Systemic lupus erythematosus (SLE)

Reserved for you.